ArticleStem cell research & therapy2026
CNOT3 resists ovarian aging by accelerating oocyte maturation and promoting ESCs differentiation.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOvarian aging (OA), which is characterized by a decline in the quality and quantity of oocytes, represents a major challenge in reproductive medicine. However, the therapeutic targets and therapeutic methods of OA remain poorly defined. Previous studies have suggested that the embryonic stem cells (ESCs) resist mammalian OA, yet the underlying molecular mechanisms are unclear.
methodsTo assess CNOT3's role in OA and oocyte maturation, we employed RT-qPCR, Western blotting, micro-injection, and RNA seq. RNA-seq, RT-qPCR, and Western blot were used to prove the effects of Cnot3 on the differentiation of mouse ESCs into primordial germ cell-like cells (PGCLCs). Mouse ESCs were injected into mice to evaluate the therapeutic benefit of ESCs on OA.
resultsIn this study, we demonstrated that the CCR4-NOT transcription complex subunit 3 (CNOT3) played a critical regulator of OA resistance. Our results revealed that the expression of CNOT3 significantly decreased in aging ovaries of pigs and mice, compared with young ovaries. Using RNA-seq and micro-injection, we proved that CNOT3 resisted porcine OA by accelerating oocyte maturation. Moreover, Cnot3 upregulated the expressions of pluripotent genes in mouse ESCs and promoted the differentiation of ESCs into PGCLCs in vitro. Importantly, we found that tail vein injection of ESCs resisted mouse OA, while the therapeutic effects of ESCs on OA were reversed by knockdown of Cnot3.
conclusionOverall, our results indicated that CNOT3 counteracted OA and enhanced the therapeutic benefit of ESCs on OA. These findings will provide useful information for the improvement of therapeutic methods of OA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.